報價延遲最少15分鐘:2025/01/31 13:43 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.62/--
|
|
企業價值
--
|
| 資產負債 |
|
每股賬面淨值
不適用
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/31 13:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extendingplatform. |